CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 (CORONA)

Clinical Trial ID NCT04378244

Rank	Title	Journal	Year	PubWeight™‹?›
1	A Novel Coronavirus from Patients with Pneumonia in China, 2019.	N Engl J Med	2020	7.78
2	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.	Cell	2020	3.29
3	Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.	Mol Ther	2009	0.90
4	Rexin-G, a targeted genetic medicine for cancer.	Expert Opin Biol Ther	2010	0.86
5	Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze.	Invest Ophthalmol Vis Sci	2002	0.85
6	Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein.	Hum Gene Ther	1997	0.84
7	Molecular-cloning of the human cycg1 gene encoding a g-type cyclin - overexpression in human osteosarcoma cells.	Oncol Rep	1994	0.80
8	Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct.	Int J Mol Med	2001	0.80
9	Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation.	Circulation	1997	0.79
10	Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury.	Int J Mol Med	2000	0.79
11	Lesion-targeted injectable vectors for vascular restenosis.	Hum Gene Ther	2001	0.76